Investigational and not approved by the FDA. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Selepressin

Investigational

Vasopressin V1a receptor agonist

Also known as: Fe202158, Fe 202158, selepresina, selepressine, FE-202158, selepressinum

Evidence score

54/ 100

Moderate evidence

A real evidence base, with gaps

Regulatory standing. In clinical trials, not yet approved
Limited human data. Some human data exists, not conclusive
Registered human trials. 1 registered study on ClinicalTrials.gov, most advanced Phase 3
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Selepressin is a synthetic peptide analog of vasopressin designed to selectively activate the V1a receptor, which constricts blood vessels and raises blood pressure. It was developed by Ferring Pharmaceuticals as a potential treatment for low blood pressure in septic shock, with the aim of avoiding effects linked to other vasopressin receptors.

What the evidence shows

Automatic summaryLimited human data

Selepressin is not FDA-approved. It reached a registered Phase 3 trial in septic shock (the SEPSIS-ACT trial), which was stopped for futility after it did not improve the main outcome compared with placebo, so no clinical benefit has been established in humans.

Key facts

Molecular formula

C46H73N13O11S2

Molecular weight

1048.3 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

1registered studies

Phase 3most advanced phase

0completed (sample)

0recruiting (sample)

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

Phase 3TerminatedNCT02508649

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

35papers referencing Selepressin

Vasoplegia treatments: the past, the present, and the future.

Crit Care2018

Vasopressor therapy in critically ill patients with shock.

Intensive Care Med2019

Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis.

Am J Respir Crit Care Med2016

Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial.

JAMA2019

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.